Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Women Infertility pipeline market report provides a comprehensive overview of the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects.
Women Infertility Pipeline Drugs Market by Key Targets
In the Women Infertility pipeline drugs market, the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.
Key Targets in the Women Infertility Pipeline Drugs Market
For more target insights, download a free report sample
Key MoA in the Women Infertility Pipeline Drugs Market
Follicle Stimulating Hormone Receptor Agonist has the highest share in the Women Infertility Pipeline Drugs Market. The other key mechanisms of action are Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.
Women Infertility Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Women Infertility Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Women Infertility pipeline drug market are oral, subcutaneous, intravenous, intramuscular, vaginal, parenteral, injection, intraarterial, intracavitary, and intrauterine. Oral has the maximum number of pipeline products.
Women Infertility Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Women Infertility Pipeline Drugs Market
The key molecule types in the Women Infertility pipeline drugs market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy. Small molecule has the maximum number of pipeline products.
Women Infertility Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Women Infertility Pipeline Drugs Market
Some of the major companies in the Women Infertility pipeline drugs market are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.
Women Infertility Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Women Infertility Pipeline Drugs Market Overview
| Key Targets | Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype |
| Key Mechanisms of Action | Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist |
| Key Routes of Administration | Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine |
| Key Molecule Types | Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy |
| Major Companies | Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility
- The pipeline guide reviews pipeline therapeutics for Women Infertility by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Women Infertility
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
In the Women Infertility pipeline drugs market the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.
In the Women Infertility pipeline drugs market the key mechanisms of action are Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.
The key routes of administration in the Women Infertility pipeline drug market Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine. Oral has the maximum number of pipeline products.
The key molecule types in the Women Infertility pipeline drug market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy.
In the Women Infertility pipeline drugs market the major companies are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.